Novavax (NVAX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
18 Jun, 2026Opening remarks and agenda
CEO welcomed attendees, introduced board members and executive team, and outlined the meeting structure.
Meeting agenda and rules of conduct were made available on the virtual platform.
Board and executive committee updates
Election of three Class I directors for a three-year term was proposed and qualifications referenced in the proxy statement.
Shareholder proposals
Proposals included director elections, advisory approval of executive compensation, amendments to stock incentive and employee stock purchase plans, and ratification of the independent auditor.
No additional proposals were introduced by stockholders.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Novavax
- Q2 2026 revenue dropped to $57M as milestone payments fell, but product sales rose 76%.NVAX
Q2 2026 - Sanofi partnership, pipeline expansion, and lean operations drive growth and financial strength.NVAX
Jefferies 2024 Global Healthcare Conference - Immediate monetization, major partnerships, and cost cuts drive profitability by 2028.NVAX
Jefferies Global Healthcare Conference 2026 - Pivoted to a platform strategy, securing major deals and targeting profitability by 2028.NVAX
Leerink Global Healthcare Conference 2026 - Partnerships and R&D innovation drive growth, targeting billions in royalties and a $100B+ market.NVAX
Corporate presentation - Strategic shift to Matrix-M partnerships drives growth, cost reduction, and long-term profitability.NVAX
Bank of America Global Healthcare Conference 2026 - Q1 2026 revenue fell 79% as Matrix-M partnerships and cost cuts support future profitability.NVAX
Q1 2026 - Sanofi partnership, pipeline growth, and cost cuts target profitability by 2027.NVAX
Goldman Sachs 46th Annual Global Healthcare Conference - Q1 2025 net income hit $519M on $667M revenue, with guidance raised and strong liquidity.NVAX
Q1 2025